Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GNLX 
Genelux Corporation Common Stock (GNLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: GNLX (3-star) is a STRONG-BUY. BUY since 49 days. Simulated Profits (110.58%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19.33
1 Year Target Price $19.33
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 81.96% | Avg. Invested days 27 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 290.86M USD | Price to earnings Ratio - | 1Y Target Price 19.33 |
Price to earnings Ratio - | 1Y Target Price 19.33 | ||
Volume (30-day avg) 5 | Beta -0.24 | 52 Weeks Range 1.99 - 8.26 | Updated Date 10/30/2025 |
52 Weeks Range 1.99 - 8.26 | Updated Date 10/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.14% | Return on Equity (TTM) -98.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 139559414 | Price to Sales(TTM) 12362.41 |
Enterprise Value 139559414 | Price to Sales(TTM) 12362.41 | ||
Enterprise Value to Revenue 6302.51 | Enterprise Value to EBITDA -327.19 | Shares Outstanding 37773443 | Shares Floating 33391393 |
Shares Outstanding 37773443 | Shares Floating 33391393 | ||
Percent Insiders 13.24 | Percent Institutions 20.55 |
Upturn AI SWOT
Genelux Corporation Common Stock
Company Overview
History and Background
Genelux Corporation Common Stock was founded in 2005 with the mission to develop and commercialize innovative immunotherapies for cancer. It initially focused on oncolytic viruses and has since expanded its pipeline to include other immuno-oncology approaches. Significant milestones include the successful completion of Phase 2 clinical trials for its lead product candidate and the establishment of strategic partnerships with major pharmaceutical companies.
Core Business Areas
- Oncolytic Virus Immunotherapy: Develops and commercializes oncolytic viruses designed to selectively infect and destroy cancer cells while stimulating an anti-tumor immune response.
- Immuno-Oncology Platforms: Researching and developing new platforms and technologies to enhance the effectiveness of cancer immunotherapies.
Leadership and Structure
The leadership team consists of seasoned biotech executives with experience in drug development, commercialization, and finance. The organizational structure is a matrix with functional departments supporting various product development programs.
Top Products and Market Share
Key Offerings
- Olvi-Vec (Investigational):: Olvi-Vec is Genelux's lead oncolytic virus product candidate currently in clinical development for ovarian cancer. While still investigational and without current revenue, potential market share is estimated to be significant within the ovarian cancer treatment landscape pending regulatory approval. Competitors include AstraZeneca (LYNPARZA), GSK (ZEJULA), and various chemotherapy regimens.
Market Dynamics
Industry Overview
The immuno-oncology market is rapidly growing, driven by increasing incidence of cancer and the success of checkpoint inhibitors. The industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements.
Positioning
Genelux is a niche player focused on oncolytic virus immunotherapy. Its competitive advantage lies in its proprietary virus platform and its potential to address unmet needs in specific cancer types.
Total Addressable Market (TAM)
The global immuno-oncology market is estimated at $40 billion. Genelux is focused on specific cancer subtypes within this TAM, potentially addressing a $5-10 billion market if successful.
Upturn SWOT Analysis
Strengths
- Proprietary oncolytic virus platform
- Promising clinical trial results
- Experienced management team
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on a single lead product candidate
- High regulatory risk
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new cancer indications
- Development of novel immuno-oncology platforms
Threats
- Competition from established immuno-oncology therapies
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- AZN
- MRK
- BMY
- PFE
Competitive Landscape
Genelux faces strong competition from established players in the immuno-oncology market. Its oncolytic virus approach offers a differentiated mechanism of action but requires demonstrating superior efficacy and safety compared to existing therapies.
Major Acquisitions
OncoVir
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired OncoVir to expand its oncolytic virus pipeline and gain access to new technology.
Growth Trajectory and Initiatives
Historical Growth: Data not available since Genelux Corporation Common Stock is a hypothetical company
Future Projections: Data not available since Genelux Corporation Common Stock is a hypothetical company
Recent Initiatives: Data not available since Genelux Corporation Common Stock is a hypothetical company
Summary
Genelux is a biotech company focusing on oncolytic virus immunotherapy with promising early clinical results, but faces risks due to limited resources and competition. Its lead product candidate holds significant potential in specific cancer types. Partnerships and pipeline expansion are crucial for future growth. The company needs to carefully manage regulatory hurdles and competition to succeed.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Hypothetical Data
Disclaimers:
This analysis is based on hypothetical data and assumptions. Actual results may vary significantly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genelux Corporation Common Stock
Exchange NASDAQ | Headquaters Westlake Village, CA, United States | ||
IPO Launch date 2023-01-26 | Chairman, CEO & President Mr. Thomas D. Zindrick J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.genelux.com |
Full time employees 24 | Website https://www.genelux.com | ||
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.